Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03714022 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT03714022 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 140 participants.
The verdict
NCT03714022, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
The main objective of this study is to compare the pharmacokinetics (PK) of the abatacept drug product converted from drug substance by a new drug substance process (Treatment A) relative to the current drug substance process (Treatment B) following a single dose (750 mg) intravenous (IV) infusion in healthy participants.
Interventions
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2018-11-09 |
| Est. Completion | 2019-04-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03714022
The ClinicalTrials.gov registry entry for NCT03714022 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abatacept is the first listed.
NCT03714022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03714022 about?
NCT03714022 is a clinical study titled "A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes". The main objective of this study is to compare the pharmacokinetics (PK) of the abatacept drug product converted from drug substance by a new drug substance process (Treatment A) relative to the current drug substance process (Treatment B) following a single dose (750 mg) intravenous (IV) infusion i...
What is the current status of trial NCT03714022?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2018-11-09. Estimated completion is 2019-04-02.
What interventions are being tested in trial NCT03714022?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT03714022?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.